Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
- Conditions
- Abdominal Cancer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 100
- Registration Number
- NCT06604533
- Locations
- 🇦🇺
GenesisCare Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 40
- Registration Number
- NCT06441747
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Monash Medical Centre, Clayton, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: Continuation of somatostatin analoguesDrug: Cessation of somatostatin analogues
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 78
- Registration Number
- NCT06345079
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 54
- Registration Number
- NCT06290505
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Border Medical Oncology, Albury, New South Wales, Australia
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 20
- Registration Number
- NCT06094140
- Locations
- 🇦🇺
GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Warringal Private Hospital, Melbourne, Victoria, Australia
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
- Conditions
- Oligometastatic DiseaseColorectal Cancer
- Interventions
- Procedure: Local Ablative TherapyProcedure: Standard first-line systemic treatment
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 75
- Registration Number
- NCT05862051
- Locations
- 🇦🇺
Eastern Health, Box Hill, Victoria, Australia
🇦🇺The Northern Hospital, Epping, Victoria, Australia
🇦🇺Peter MaCallum Cancer Centre, Melbourne, Victoria, Australia
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 90
- Registration Number
- NCT05694936
- Locations
- 🇦🇺
Eben-Marie Garzina, Ballarat Central, Victoria, Australia
🇦🇺Southern Adelaide Local Health Network Incorporated, Bedford Park, South Australia, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 158
- Registration Number
- NCT05042128
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
🇦🇺Flinders Medical Centre, Adelaide, South Australia, Australia
RegoNivo vs Standard of Care Chemotherapy in AGOC
- Conditions
- Gastro-Oesophageal Cancer
- Interventions
- Biological: NivolumabDrug: Trifluridine/Tipracil
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 450
- Registration Number
- NCT04879368
- Locations
- 🇦🇺
Austin Health, Melbourne, Victoria, Australia
🇦🇹Medizinische Universitaet Wien, Vienna, Austria
🇦🇹Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: mFOLFIRINOXRadiation: Stereotactic Radiotherapy (SBRT)Procedure: Pancreatoduodenectomy (Whipple procedure)
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 120
- Registration Number
- NCT04089150
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia